TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer. And more agents could be around the corner.

On Friday, FDA granted accelerated approval to the humanized mAb against PD-L1 in combination with Abraxane nab-paclitaxel to treat PD-L1-positive metastatic TNBC.

TNBC

Read the full 646 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE